Iminodibenzyl class antipsychotics for schizophrenia: a systematic review and meta-analysis of carpipramine, clocapramine, and mosapramine

Iminodibenzyl class antipsychotics for schizophrenia: a systematic review and meta-analysis of carpipramine, clocapramine, and mosapramine

Taro Kishi, Shinji Matsunaga, Yuki Matsuda, Nakao Iwata Department of Psychiatry, Fujita Health University School of Medicine, Toyoake, Japan Background: We conducted a meta-analysis of the iminodibenzyl antipsychotics carpipramine, clocapramine, and mosapramine, which are classified as second-gen...

Full description

Bibliographic Details
Main Authors:	Kishi T, Matsunaga S, Matsuda Y, Iwata N
Format:	Article
Language:	English
Published:	Dove Medical Press 2014-12-01
Series:	Neuropsychiatric Disease and Treatment
Online Access:	http://www.dovepress.com/iminodibenzyl-class-antipsychotics-for-schizophrenia-a-systematic-revi-peer-reviewed-article-NDT

Similar Items

Aripiprazole for the management of schizophrenia in the Japanese population: a systematic review and meta-analysis of randomized controlled trials
by: Kishi T, et al.
Published: (2015-02-01)

Iminodibenzyl induced redirected COX-2 activity inhibits breast cancer progression
by: Harshit Shah, et al.
Published: (2021-09-01)

Atypical antipsychotics in the treatment of schizophrenia: systematic overview and meta-regression analysis.
by: Geddes, J, et al.
Published: (2000)

Adverse effects of antipsychotics on sleep in patients with schizophrenia. Systematic review and meta-analysis
by: Yarmila Elena Valencia Carlo, et al.
Published: (2023-06-01)

Efficacy and tolerability of aripiprazole once monthly for schizophrenia: a systematic review and meta-analysis of randomized controlled trials
by: Oya K, et al.
Published: (2015-09-01)

Suvorexant for Primary Insomnia: A Systematic Review and Meta-Analysis of Randomized Placebo-Controlled Trials.
by: Taro Kishi, et al.
Published: (2015-01-01)

Effects of antipsychotics on heart rate in treatment of schizophrenia: a systematic review and meta-analysis
by: Maximilian Huhn, et al.
Published: (2022-06-01)

Association of metabotropic glutamate receptor 3 gene polymorphisms with schizophrenia risk: evidence from a meta-analysis
by: Yang X, et al.
Published: (2015-03-01)

Outcomes of patients with schizophrenia who discontinued long‐acting injectable antipsychotic therapy due to adverse events: A chart review
by: Taro Kishi, et al.
Published: (2021-09-01)

A systematic review of atypical antipsychotic drugs in schizophrenia
by: A-.M. Bagnall, et al.
Published: (2003-01-01)

Early prediction of blonanserin response in Japanese patients with schizophrenia
by: Kishi T, et al.
Published: (2014-09-01)

Atypical antipsychotics in the treatment of schizophrenia: Systematic review, meta-regression and evidence-based treatment recommendations
by: Geddes, J, et al.
Published: (2000)

Long-term effects of antipsychotics on mortality in patients with schizophrenia: a systematic review and meta-analysis
by: Ningning Jia, et al.
Published: (2022-12-01)

Paliperidone palmitate vs. paliperidone extended-release for the acute treatment of adults with schizophrenia: a systematic review and pairwise and network meta-analysis
by: Taro Kishi, et al.
Published: (2022-12-01)

The effects of memantine on behavioral disturbances in patients with Alzheimer's disease: a meta-analysis
by: Kishi T, et al.
Published: (2017-07-01)

Atypical antipsychotics in the treatment of schizophrenia
by: Swiss Medical Weekly
Published: (2003-02-01)

Hyperprolactinemia during antipsychotics treatment increases the level of coagulation markers
by: Ishioka M, et al.
Published: (2015-02-01)

Antipsychotic monotherapy and polypharmacy in the naturalistic treatment of schizophrenia with atypical antipsychotics
by: Correll Christoph, et al.
Published: (2005-05-01)

Long-term antipsychotic treatment in schizophrenia: systematic review and network meta-analysis of randomised controlled trials
by: Ying Jiao Zhao, et al.
Published: (2016-01-01)

Pharmacological Interventions to Treat Antipsychotic-Induced Dyslipidemia in Schizophrenia Patients: A Systematic Review and Meta Analysis
by: Pruntha Kanagasundaram, et al.
Published: (2021-03-01)

Reappraising the variability of effects of antipsychotic medication in schizophrenia: a meta-analysis
by: McCutcheon, RA, et al.
Published: (2022)

Conformation Control of Iminodibenzyl-Based Thermally Activated Delayed Fluorescence Material by Tilted Face-to-Face Alignment With Optimal Distance (tFFO) Design
by: Yu Kusakabe, et al.
Published: (2020-08-01)

Sex Selection Bias in Schizophrenia Antipsychotic Trials—An Update Systematic Review
by: Lais Fonseca, et al.
Published: (2021-05-01)

Antipsychotic polypharmacy and metabolic syndrome in schizophrenia: a review of systematic reviews
by: Sharea Ijaz, et al.
Published: (2018-09-01)

Systematic review of the economic aspects of nonadherence to antipsychotic medication in patients with schizophrenia
by: Dilla T, et al.
Published: (2013-04-01)

Efficacy and Tolerance of Antipsychotics Used for the Treatment of Patients Newly Diagnosed with Schizophrenia: A Systematic Review and Meta-Analysis
by: Zina Sherzad Qadir, et al.
Published: (2023-11-01)

Traditional Chinese Medicine Decoction Combined With Antipsychotic for Chronic Schizophrenia Treatment: A Systematic Review and Meta-analysis
by: Xiao-Jie Shi, et al.
Published: (2021-01-01)

Efficacy, tolerability, and safety of lurasidone for acute schizophrenia: A systematic review and network meta‐analysis of phase 3 trials in Japan
by: Taro Kishi, et al.
Published: (2020-09-01)

Effect of antipsychotics on serum uric acid in patients with schizophrenia： a Meta-analysis
by: Zhang Wenyan, et al.
Published: (2021-12-01)

Atypical antipsychotics in the treatment of schizophrenia - Reply
by: Geddes, J, et al.
Published: (2001)

Polypharmacy Management of Antipsychotics in Patients with Schizophrenia
by: Hiroyuki Kamei
Published: (2022-11-01)

ADHERENCE TO ANTIPSYCHOTIC MEDICATION IN SCHIZOPHRENIA PATIENTS
by: Peter Pregelj
Published: (2009-01-01)

New atypical antipsychotics for schizophrenia: iloperidone
by: Silvio Caccia, et al.
Published: (2010-02-01)

Cost of antipsychotic polypharmacy in the treatment of schizophrenia
by: Correll Christoph U, et al.
Published: (2008-04-01)

Antipsychotic agents: efficacy and safety in schizophrenia
by: de Ara&uacute;jo AN, et al.
Published: (2012-11-01)

Different presence of Chlamydia pneumoniae, herpes simplex virus type 1, human herpes virus 6, and Toxoplasma gondii in schizophrenia: meta-analysis and analytical study
by: Gutiérrez-Fernández J, et al.
Published: (2015-03-01)

Unresolved Issues for Utilization of Atypical Antipsychotics in Schizophrenia: Antipsychotic Polypharmacy and Metabolic Syndrome
by: Sang Won Jeon, et al.
Published: (2017-10-01)

The Novel Antipsychotic Lumateperone (Iti-007) in the Treatment of Schizophrenia: A Systematic Review
by: Giulio Longo, et al.
Published: (2023-11-01)

A Systematic Review on the Effectiveness of Antipsychotic Drugs on the Quality of Life of Patients with Schizophrenia
by: Gaia Sampogna, et al.
Published: (2023-11-01)

Blinding successfulness in antipsychotic trials of acute treatment for schizophrenia: a systematic review
by: Toshi A Furukawa, et al.
Published: (2023-06-01)